Imatinib mesylate (IM), a specific inhibitor of the BCR-ABL tyrosine kinase, is a well-established first-line treatment for chronic myeloid leukemia (CML). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.